Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2009;104:1095-1102
Published online before print April 2, 2009, doi: 10.1161/CIRCRESAHA.108.192138
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
104/9/1095    most recent
CIRCRESAHA.108.192138v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barcelos, L. S.
Right arrow Articles by Madeddu, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barcelos, L. S.
Right arrow Articles by Madeddu, P.
Related Collections
Right arrow Angiogenesis
Right arrow Animal models of human disease
Right arrow Type 1 diabetes
Right arrow Other Vascular biology
Right arrowRelated Article
(Circulation Research. 2009;104:1095.)
© 2009 American Heart Association, Inc.


Integrative Physiology

Human CD133+ Progenitor Cells Promote the Healing of Diabetic Ischemic Ulcers by Paracrine Stimulation of Angiogenesis and Activation of Wnt Signaling

Lucíola S. Barcelos*, Cécile Duplaa*, Nicolle Kränkel*, Gallia Graiani*, Gloria Invernici, Rajesh Katare, Mauro Siragusa, Marco Meloni, Ilaria Campesi, Manuela Monica, Andreas Simm, Paola Campagnolo, Giuseppe Mangialardi, Lara Stevanato, Giulio Alessandri, Costanza Emanueli, Paolo Madeddu

From the Bristol Heart Institute (L.S.B., N.K., R.K., M.S., M. Meloni, P.C., G.M., C.E., P.M.), Department of Clinical Science at South Bristol, University of Bristol, United Kingdom; Institut National de la Santé et de la Recherche Médicale U828 (C.D.), University Victor Segalen-Bordeaux II, France; Department of Pathology (G.G., M. Monica), University of Parma, Italy; Neurobiology and Neuroregenerative Therapies Unit (G.I., G.A.), Carlo Besta Neurological Institute, Milan, Italy; Experimental Medicine and Gene Therapy Section (I.C.), National Institute of Biostructures and Biosystems (INBB), Osilo (Sassari), Italy; Department of Cardio-Thoracic Surgery (A.S.), Martin-Luther University of Halle-Wittenberg, Halle, Germany; and Department Stem Cell Discovery (L.S.), ReNeuron Ltd, Guildford, United Kingdom.

Correspondence to Paolo Madeddu, MD, CS, FAHA, Bristol Heart Institute, University of Bristol, Upper Maudlin St, Bristol, BS2 8HW, United Kingdom. E-mail madeddu{at}yahoo.com

We evaluated the healing potential of human fetal aorta-derived CD133+ progenitor cells and their conditioned medium (CD133+ CCM) in a new model of ischemic diabetic ulcer. Streptozotocin-induced diabetic mice underwent bilateral limb ischemia and wounding. One wound was covered with collagen containing 2x104 CD133+ or CD133 cells or vehicle. The contralateral wound, covered with only collagen, served as control. Fetal CD133+ cells expressed high levels of wingless (Wnt) genes, which were downregulated following differentiation into CD133 cells along with upregulation of Wnt antagonists secreted frizzled-related protein (sFRP)-1, -3, and -4. CD133+ cells accelerated wound closure as compared with CD133 or vehicle and promoted angiogenesis through stimulation of endothelial cell proliferation, migration, and survival by paracrine effects. CD133+ cells secreted high levels of vascular endothelial growth factor (VEGF)-A and interleukin (IL)-8. Consistently, CD133+ CCM accelerated wound closure and reparative angiogenesis, with this action abrogated by coadministering the Wnt antagonist sFRP-1 or neutralizing antibodies against VEGF-A or IL-8. In vitro, these effects were recapitulated following exposure of high-glucose-primed human umbilical vein endothelial cells to CD133+ CCM, resulting in stimulation of migration, angiogenesis-like network formation and induction of Wnt expression. The promigratory and proangiogenic effect of CD133+ CCM was blunted by sFRP-1, as well as antibodies against VEGF-A or IL-8. CD133+ cells stimulate wound healing by paracrine mechanisms that activate Wnt signaling pathway in recipients. These preclinical findings open new perspectives for the cure of diabetic ulcers.


Key Words: ischemia • wound healing • diabetes • stem cells • angiogenesis


Related Article:

Vascular Progenitor Cells in Diabetes Mellitus: Roles of Wnt Signaling and Negatively Charged Low-Density Lipoprotein
Chu-Huang Chen, Richard A.F. Dixon, Liang-Yin Ke, and James T. Willerson
Circ. Res. 2009 104: 1038-1040. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
Circ. Res.Home page
R. Ascione and P. Madeddu
Risk and Benefit of CD133+ Progenitors
Circ. Res., July 17, 2009; 105(2): e2 - e2.
[Full Text] [PDF]


Home page
Circ. Res.Home page
C.-H. Chen, R. A.F. Dixon, L.-Y. Ke, and J. T. Willerson
Vascular Progenitor Cells in Diabetes Mellitus: Roles of Wnt Signaling and Negatively Charged Low-Density Lipoprotein
Circ. Res., May 8, 2009; 104(9): 1038 - 1040.
[Full Text] [PDF]